2.75 USD
+0.03 (+1.1%)
2.7501 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to BTMD. BTMD was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 25.87%, BTMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 45.22%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 14.72%, BTMD belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
BTMD has a Operating Margin of 16.09%. This is amongst the best in the industry. BTMD outperforms 85.86% of its industry peers.
BTMD's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 72.23%, BTMD is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
BTMD has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.31 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a Altman-Z score of 2.31. This is in the better half of the industry: BTMD outperforms 61.26% of its industry peers.
BTMD has a debt to FCF ratio of 4.18. This is a neutral value as BTMD would need 4.18 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.18, BTMD belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.31 |
ROIC/WACC4.91
WACC9.21%
2.3 Liquidity
A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD has a worse Current ratio (1.01) than 82.72% of its industry peers.
BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 85.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.44% in the last year.
The Revenue has been growing by 12.38% on average over the past years. This is quite good.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
BTMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 3.16, which indicates a rather cheap valuation of BTMD.
97.91% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.59, BTMD is valued rather cheaply.
The Price/Forward Earnings ratio is 10.50, which indicates a very decent valuation of BTMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 86.39% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.16 | ||
| Fwd PE | 10.5 |
4.2 Price Multiples
94.24% of the companies in the same industry are more expensive than BTMD, based on the Enterprise Value to EBITDA ratio.
98.43% of the companies in the same industry are more expensive than BTMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.65 | ||
| EV/EBITDA | 6.83 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y9.09%
EPS Next 3Y9.09%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.75
+0.03 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners63.13%
Inst Owner Change-8.25%
Ins Owners10.06%
Ins Owner Change0%
Market Cap125.56M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target5.2 (89.09%)
Short Float %3.52%
Short Ratio8.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.74%
PT rev (3m)-5.74%
EPS NQ rev (1m)-23.08%
EPS NQ rev (3m)-11.77%
EPS NY rev (1m)23.48%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.16 | ||
| Fwd PE | 10.5 | ||
| P/S | 0.64 | ||
| P/FCF | 3.65 | ||
| P/OCF | 3.14 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.83 |
EPS(TTM)0.87
EY31.64%
EPS(NY)0.26
Fwd EY9.52%
FCF(TTM)0.75
FCFY27.41%
OCF(TTM)0.88
OCFY31.85%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.31 |
F-Score7
WACC9.21%
ROIC/WACC4.91
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 229.18% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.